Clinical and economic burden of adverse drug reactions
暂无分享,去创建一个
[1] Lisa Wang,et al. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Ioannidis,et al. Reporting of safety data from randomised trials , 1998, The Lancet.
[3] J. Cornell,et al. Adverse Events Related to Drugs and Drug Withdrawal in Nursing Home Residents , 1993, Journal of the American Geriatrics Society.
[4] J. Aronson. Distinguishing Hazards and Harms, Adverse Drug Effects and Adverse Drug Reactions , 2013, Drug Safety.
[5] H. Cheng. Randomized, controlled trials: Gold or bronze? , 2006, Journal of the American Medical Directors Association.
[6] B. Charlton,et al. The rise and fall of EBM. , 1998, QJM : monthly journal of the Association of Physicians.
[7] Charles Vincent,et al. Hospital staff should use more than one method to detect adverse events and potential adverse events: incident reporting, pharmacist surveillance and local real-time record review may all have a place , 2007, Quality and Safety in Health Care.
[8] G. Trifirò,et al. Adverse drug events in emergency department population: a prospective Italian study , 2005, Pharmacoepidemiology and drug safety.
[9] J. G. Evans,et al. Evidence-based and evidence-biased medicine. , 1995, Age and ageing.
[10] F. Haramburu,et al. Incidence of serious adverse drug reactions in general practice: A prospective study , 2001, Clinical pharmacology and therapeutics.
[11] C. Richards,et al. Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults , 2007, Annals of Internal Medicine.
[12] N. Oswald,et al. Applying research evidence to individuals in primary care: a study using non-rheumatic atrial fibrillation. , 1999, Family practice.
[13] L. Caplan,et al. Evidence based medicine: concerns of a clinical neurologist , 2001, Journal of neurology, neurosurgery, and psychiatry.
[14] J. W. A. S. Sander,et al. Difficulties in extrapolating from clinical trial data to clinical practice: The case of antiepileptic drugs , 1997, Neurology.
[15] Isabelle Boutron,et al. Reporting of safety results in published reports of randomized controlled trials. , 2009, Archives of internal medicine.
[16] M. Pirmohamed,et al. Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes , 2009, PloS one.
[17] G. Passalacqua,et al. Adverse drug reactions as the cause of emergency department admission: focus on the elderly , 2010, Immunopharmacology and immunotoxicology.
[18] A. Nichol,et al. Challenging issues in randomised controlled trials. , 2010, Injury.
[19] A. Wood. The safety of new medicines: the importance of asking the right questions. , 1999, JAMA.
[20] D. Bates,et al. The Costs of Adverse Drug Events in Hospitalized Patients , 1997 .
[21] Nicholas Moore,et al. Differences between clinical trials and postmarketing use. , 2003, British journal of clinical pharmacology.
[22] M. Haggard,et al. Generalisability of clinical trials in otitis media with effusion. , 2001, International journal of pediatric otorhinolaryngology.
[23] E. Hannan. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. , 2008, JACC. Cardiovascular interventions.
[24] E. Hemminki. Study of information submitted by drug companies to licensing authorities. , 1980, British medical journal.
[25] R. Beyth,et al. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. , 1993, The American journal of medicine.
[26] N. Black. Why we need observational studies to evaluate the effectiveness of health care , 1996, BMJ.
[27] J. Hernandez‐Nino,et al. Size isn't everything. , 2008, Journal of thrombosis and haemostasis : JTH.
[28] D. Classen,et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. , 1997, JAMA.
[29] P. Rothwell,et al. External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.
[30] D. Bates,et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. , 1997, Critical care medicine.
[31] J. Ioannidis,et al. Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement , 2004, Annals of Internal Medicine.
[32] J. Cooper. Probable Adverse Drug Reactions in a Rural Geriatric Nursing Home Population: A Four‐Year Study , 1996, Journal of the American Geriatrics Society.
[33] T. Steiner,et al. Towards a model stroke trial. The single-centre naftidrofuryl study. , 1986, Neuroepidemiology.
[34] P Impicciatore,et al. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. , 2001, British journal of clinical pharmacology.
[35] W. Weiner. What do clinical trials tell us about treating patients? , 2009, Parkinsonism & related disorders.
[36] Gillian E. Caughey,et al. The prescribing cascade , 2011 .
[37] M. Pirmohamed,et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.
[38] E. Autret‐Leca,et al. Are incorrectly used drugs more frequently involved in adverse drug reactions? A prospective study , 2005, European Journal of Clinical Pharmacology.
[39] A. Feinstein,et al. Problems in the "evidence" of "evidence-based medicine". , 1997, The American journal of medicine.
[40] C. Adams,et al. Randomized controlled trials in schizophrenia: a critical perspective on the literature , 2002, Acta psychiatrica Scandinavica.
[41] David W Bates,et al. The Costs Associated With Adverse Drug Events Among Older Adults in the Ambulatory Setting , 2005, Medical care.
[42] Pamela S. Fleming,et al. Potentially inappropriate medication use in hospitalized older adults : A DUE using the full Beers criteria , 2008 .
[43] S. Ogle,et al. The Epidemiology of Serious Adverse Drug Reactions Among the Elderly , 1999, Drugs & aging.
[44] P. Routledge,et al. Adverse drug reactions in elderly patients. , 2003, British journal of clinical pharmacology.
[45] Yumi Kameyama,et al. Factors Associated with Prolonged Hospital Stay in a Geriatric Ward of a University Hospital in Japan , 2012, Journal of the American Geriatrics Society.
[46] J. Cairns. Stroke prevention in atrial fibrillation trial. , 1991, Circulation.
[47] T. Buclin,et al. Rate, type, and cost of adverse drug reactions in emergency department admissions. , 2001, European journal of internal medicine.
[48] S D Small,et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. , 1998, JAMA.
[49] R. Cebul,et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation , 1996, Journal of General Internal Medicine.
[50] M. Pirmohamed,et al. Which drugs cause preventable admissions to hospital? A systematic review. , 2007, British journal of clinical pharmacology.
[51] R. Tallis,et al. Inappropriate medication is a major cause of adverse drug reactions in elderly patients. , 1992, Age and ageing.
[52] C. Binnie. Design of clinical antiepileptic drug trials , 1995, Seizure.
[53] M Egger,et al. The causes and effects of socio-demographic exclusions from clinical trials. , 2005, Health technology assessment.
[54] J R Hampton,et al. Variations in the use of coronary arteriography in the UK: the RITA trial coronary arteriogram register. , 1995, QJM : monthly journal of the Association of Physicians.
[55] C. Weijer,et al. Reporting the study populations of clinical trials. Clear transmission or static on the line? , 2000, Journal of clinical epidemiology.
[56] C. Naylor. Grey zones of clinical practice: some limits to evidence-based medicine , 1995, The Lancet.
[57] N. Picard,et al. Is inappropriate medication use a major cause of adverse drug reactions in the elderly? , 2007, British journal of clinical pharmacology.
[58] D. Black. The Limitations of Evidence , 2015, Journal of the Royal College of Physicians of London.
[59] P. Home,et al. Observational studies: going beyond the boundaries of randomized controlled trials. , 2010, Diabetes research and clinical practice.
[60] W. K. Morgan. On evidence, embellishment and efficacy. , 1997, Journal of evaluation in clinical practice.
[61] G. Trifirò,et al. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. , 2011, Current drug metabolism.
[62] J. Rho,et al. Counting the Costs of Drug-Related Adverse Events , 1999, PharmacoEconomics.
[63] W. Wu,et al. Evaluation of outpatient adverse drug reactions leading to hospitalization. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[64] E. Topol,et al. Selection of patients with acute myocardial infarction for thrombolytic therapy. , 1990, Annals of internal medicine.